Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orilissa

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

- PMLiVE

AbbVie, Astellas and Roche teams among Communiqué finalists

2014 shortlist also includes MHP, Pegasus, Red Door, Ruder Finn and Virgo

EU flag

AbbVie’s hep C combo gets priority review in Europe

EMA to fast track drug for use in hard-to-treat genotype 1 strain of HCV

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

Humira still the biggest pharma brand

The industry’s best-selling products revealed in the latest PMLiVE Top Pharma List figures

- PMLiVE

AbbVie drops legal case against EMA

Accepts publication of new set of redacted Humira data

- PMLiVE

AbbVie uses art gallery in inflammation campaign

Aims to improve understanding of immune-mediated inflammatory diseases

- PMLiVE

AbbVie unveils its first Asian manufacturing plant

$320m facility set for Singapore

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

- PMLiVE

European Court may yet force AbbVie and InterMune to release data

Orders rethink on EMA's Humira and Esbriet injunction

- PMLiVE

AbbVie sales jump on strong Humira gains

Extra indications help boost performance of treatment for autoimmune disorders

- PMLiVE

FDA panel fails to back new use for AbbVie’s Humira

Votes 12 to 1 against new use in spondyloarthritis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links